296 related articles for article (PubMed ID: 33082550)
1. Dozens to be deliberately infected with coronavirus in UK 'human challenge' trials.
Callaway E
Nature; 2020 Oct; 586(7831):651-652. PubMed ID: 33082550
[No Abstract] [Full Text] [Related]
2. Keeping track of the SARS-CoV-2 vaccine pipeline.
Parker EPK; Shrotri M; Kampmann B
Nat Rev Immunol; 2020 Nov; 20(11):650. PubMed ID: 32989290
[TBL] [Abstract][Full Text] [Related]
3. Covid-19: Human challenge studies will see people purposefully infected with virus.
Mahase E
BMJ; 2020 Oct; 371():m4101. PubMed ID: 33093016
[No Abstract] [Full Text] [Related]
4. Covid-19 vaccines: Should we allow human challenge studies to infect healthy volunteers with SARS-CoV-2?
McPartlin SO; Morrison J; Rohrig A; Weijer C
BMJ; 2020 Nov; 371():m4258. PubMed ID: 33168564
[No Abstract] [Full Text] [Related]
5. COVID-19 vaccine trials: Duty of care and standard of prevention considerations.
Singh JA
Vaccine; 2020 Nov; 38(48):7578-7580. PubMed ID: 33069443
[No Abstract] [Full Text] [Related]
6. All eyes on a hurdle race for a SARS-CoV-2 vaccine.
Gaebler C; Nussenzweig MC
Nature; 2020 Oct; 586(7830):501-502. PubMed ID: 33077943
[No Abstract] [Full Text] [Related]
7. The Race to Develop a COVID-19 Vaccine.
Am J Nurs; 2020 Oct; 120(10):14-15. PubMed ID: 32976132
[TBL] [Abstract][Full Text] [Related]
8. Exploring uncertainty and risk in the accelerated response to a COVID-19 vaccine: Perspective from the pharmaceutical industry.
Coudeville L; Gomez GB; Jollivet O; Harris RC; Thommes E; Druelles S; Chit A; Chaves SS; Mahé C
Vaccine; 2020 Nov; 38(48):7588-7595. PubMed ID: 33097312
[TBL] [Abstract][Full Text] [Related]
9. Coronavirus vaccines get a biotech boost.
Dance A
Nature; 2020 Jul; 583(7817):647-649. PubMed ID: 32694847
[No Abstract] [Full Text] [Related]
10. Ensuring access and affordability through COVID-19 vaccine research and development investments: A proposal for the options market for vaccines.
Forman R; Anderson M; Jit M; Mossialos E
Vaccine; 2020 Sep; 38(39):6075-6077. PubMed ID: 32773244
[TBL] [Abstract][Full Text] [Related]
11. The underdog coronavirus vaccines that the world will need if front runners stumble.
Callaway E
Nature; 2020 Sep; 585(7825):332-333. PubMed ID: 32908297
[No Abstract] [Full Text] [Related]
12. What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist.
Palatnik-de-Sousa CB
Front Immunol; 2020; 11():2173. PubMed ID: 32983183
[No Abstract] [Full Text] [Related]
13. Developing Covid-19 Vaccines at Pandemic Speed.
Lurie N; Saville M; Hatchett R; Halton J
N Engl J Med; 2020 May; 382(21):1969-1973. PubMed ID: 32227757
[No Abstract] [Full Text] [Related]
14. Vaccines targeting SARS-CoV-2 tested in humans.
Edwards KM
Nat Med; 2020 Sep; 26(9):1336-1338. PubMed ID: 32839620
[No Abstract] [Full Text] [Related]
15. Understanding COVID-19 vaccine efficacy.
Lipsitch M; Dean NE
Science; 2020 Nov; 370(6518):763-765. PubMed ID: 33087460
[No Abstract] [Full Text] [Related]
16. A Call for a Three-Tiered Pandemic Public Health Strategy in Context of SARS-CoV-2.
Hanley BP; Keen S; Church G
Rejuvenation Res; 2020 Aug; 23(4):281-283. PubMed ID: 32539623
[No Abstract] [Full Text] [Related]
17. COVID-19 and Bacillus Calmette-Guérin: What is the Link?
Hegarty PK; Sfakianos JP; Giannarini G; DiNardo AR; Kamat AM
Eur Urol Oncol; 2020 Jun; 3(3):259-261. PubMed ID: 32327396
[TBL] [Abstract][Full Text] [Related]
18. Advances in skin science enable the development of a COVID-19 vaccine.
Falo LD
J Am Acad Dermatol; 2020 Oct; 83(4):1226-1227. PubMed ID: 32485211
[No Abstract] [Full Text] [Related]
19. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines: Setting Expectations Appropriately.
Heininger U
Pediatr Infect Dis J; 2020 Jul; 39(7):e123-e124. PubMed ID: 32427644
[No Abstract] [Full Text] [Related]
20. COVID-19: Small-Molecule Clinical Trials Landscape.
Ferreira LLG; Andricopulo AD
Curr Top Med Chem; 2020; 20(18):1577-1580. PubMed ID: 32862824
[No Abstract] [Full Text] [Related]
[Next] [New Search]
